The Fasolati Platform
Oral care, gut-health research and a clearer view of systemic observations. One direction—with a separate evidence standard for every product, measurement and proposed action.
Lytica
Development ConceptA staged approach to oral biofilm, designed to be tested.
Lytica explores an enzyme-and-phage intervention concept. The development task is to define the finished formulation and delivery method, then evaluate safety and performance. The concept is not a prescription, an established clinical protocol or a promise of selective pathogen removal.
Define the Intervention
Specify the composition, exposure, delivery and intended use before assigning a result to Lytica. Candidate ingredients are not evidence that the combined product works.
Test the Finished Formulation
Evaluate tolerability, local outcomes and analytical interference with an appropriate comparator. Any future systemic claim would need its own evidence.
Loria
Product InformationAn oral-care product deserves product-specific information.
Ask about Loria’s current formulation, labeling, directions and purchasing details. We keep those questions separate from the broader research ambition: this page does not claim that Loria lowers bacterial vesicles or systemic inflammation, replaces prescribed care, or delivers benefits inferred from ingredient studies.
Know the Product
Request information for the exact formulation and intended use. Follow its current labeling and discuss clinical questions with your dental professional.
Keep Evidence in Scope
Our product-development standard is to test the finished formulation rather than assemble an efficacy story from its ingredients.
Development & Collaboration
Clinical and consumer contexts need their own intended-use review.
Maxoral
Professional-Channel ConceptMaxoral is a proposed professional-channel direction. Formulations, intended uses and distribution arrangements require definition and review; no prescription classification or distribution partnership is asserted here.
Fasolati
Consumer-Facing DirectionThe consumer-facing ambition is accessible product information and clearer evidence. A concept does not establish an OTC classification, a retail channel or a subscription offer.
Research-use and general-wellness guidance do not themselves classify a proposed assay, software feature or product claim. FDA research-use guidance and FDA general-wellness guidance inform that review.
Gut Stack
Research & DevelopmentAsk when a gut-focused approach adds value—not assume it always does.
The Gut Stack is a research direction for evaluating defined nutrition or microbiome interventions. Its components and benefits remain to be established. It is not a barrier-restoration protocol and is not matched to a personal gut-integrity score.
Fasolati Engine
Life Board DevelopmentWhat changed? How confident are we? What next step is justified?
The proposed Life Board would keep oral, gut and systemic observations distinct—not average them into a health score. Its design calls for visible measurement quality, uncertainty and supporting evidence, including the ability to say “not interpretable yet.” It is not a live clinical service or an autonomous prescribing system.
Measure Before Interpreting
Establish what the assay measures and how reliably it detects change.
Earn the Next Decision
Test whether the result adds useful information and whether acting on it improves a meaningful outcome.